Daiichi Sankyo
Invivoscribe LeukoStrat CDx Gets CE Mark, EMA Approval
The PCR-based test is designed to help in the selection of acute myelogenous leukemia patients eligible for certain treatments.
AstraZeneca, Daiichi Sankyo Hoping to Sway FDA of Dato-DXd Benefit Despite Overall Survival Miss
Despite showing a progression-free survival benefit, the antibody-drug conjugate did not improve overall survival in HR-positive, HER2-negative or -low breast cancer.
Merck, Daiichi Sankyo to Discuss Antibody-Drug Conjugate Data in EFGR-Mutated NSCLC With Regulators
The firms will share data from the HERTHENA-Lung02 trial, in which patritumab deruxtecan improved patients' progression-free survival versus chemo.
I-SPY 2.2 Study IDs Early Breast Cancer Patients Who Benefit From Pre-Surgery Dato-DXd, Imfinzi
Premium
The adaptive basket trial, which matches patients to treatments based on complex biomarker signatures, could help shape future Phase III clinical trials.
The results, published in Nature Medicine, strengthen oncologists' understanding of Enhertu's clinical activity as a second-line option for metastatic breast cancer, experts said.